Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report

AIDS. 2007 Jul 11;21(11):1495-6. doi: 10.1097/QAD.0b013e328216f379.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1*
  • Humans
  • Lamivudine / therapeutic use
  • Middle Aged
  • Organophosphonates / therapeutic use
  • Porphyria Cutanea Tarda / chemically induced*
  • Porphyria Cutanea Tarda / virology
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use
  • Pyrones / adverse effects*
  • Pyrones / therapeutic use
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use
  • Sulfonamides
  • Tenofovir

Substances

  • HIV Protease Inhibitors
  • Organophosphonates
  • Pyridines
  • Pyrones
  • Reverse Transcriptase Inhibitors
  • Sulfonamides
  • Lamivudine
  • Tenofovir
  • Adenine
  • Ritonavir
  • tipranavir